Candel Therapeutics, Inc. CADL Return on equity

Return on equity at other companies

Bristol-Myers SquibbBMY

46.7%+17.8pp

AmgenAMGN

91.5%-7.7pp

Gilead SciencesGILD

-20.6%-53.8pp

Replimune GroupREPL

-90.9%+362pp

CG OncologyCGON

-26.4%+9.3pp

RegenxbioRGNX

-137.6%-817pp

FAQ

What is Candel Therapeutics, Inc.'s return on equity?

Candel Therapeutics, Inc. (CADL) reported return on equity of -51.2% in Q1 2026.

How has Candel Therapeutics, Inc.'s return on equity changed year-over-year?

Candel Therapeutics, Inc.'s return on equity increased by 47.9% year-over-year, from -98.1% to -51.2%.

What is the long-term trend for Candel Therapeutics, Inc.'s return on equity?

Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s return on equity has grown at a 24.3% compound annual growth rate (CAGR), from -33.6% to -64.6%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.